Advertisement

Effector Cell Requirements for Antibody-Dependent and Mitogen-Induced Cytotoxicity

  • Erwin W. Gelfand

Abstract

The generation and characterization of cytotoxic effector cells has been studied in several laboratories using a variety of xenogeneic, allogeneic and syngeneic systems (1–3). We have attempted to characterize the cell requirements for cytotoxic effector function in man in two independent assays, cytotoxic activity of non-immune effector cells for antibody-coated target cells and cytotoxic activity for target cells in the presence of mitogen. It has been suggested by several groups that antibody-dependent cytotoxicity (ADC) reflects the functional activity of B-lymphocytes whereas T-lymphocytes are active in mitogen-induced cytotoxicity (MIC) (1–4). Our earlier studies in rabbit suggested that the predominant effector cell in ADC was of monocyte-macrophage origin rather than a B-cell (5–7) and this has also been shown to be the case in mouse (8).

Keywords

Effector Cell Common Variable Immunodeficiency Peritoneal Exudate Cell Severe Combine Immunodeficiency Disease Cytotoxic Effector Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Perlmann, P. and Holm, G., Adv. Immunol. 11: 117, 1969.PubMedCrossRefGoogle Scholar
  2. 2.
    MacLennan, I.C.M., Transpl. Rev. 13: 67, 1972.Google Scholar
  3. 3.
    Perlmann, P., Perlmann, H. and Wigzell, H., Transpl. Rev. 13: 91, 1972.Google Scholar
  4. 4.
    VanBoxel, J.A., Paul, W.E., Frank, M.M. and Green, I., J. Immunol. 110: 1027, 1973.Google Scholar
  5. 5.
    Gelfand, E.W., Resch, K. and Prester, M., Europ. J. Immunol. 2: 419, 1972.CrossRefGoogle Scholar
  6. 6.
    Resch, K., Gelfand, E.W. and Prester, M., J. Immunol., 112: 792, 1974.PubMedGoogle Scholar
  7. 7.
    Gelfand, E.W., Morris, S.A. and Resch, K., J. Immunol. 114: 919, 1975.PubMedGoogle Scholar
  8. 8.
    Greenberg, A.H., Hudson, L., Shen, L. and Roitt, I.M., Nature 242: 111, 1973.CrossRefGoogle Scholar
  9. 9.
    Gelfand, E.W., Baumal, R., Huber, J., Crookston, M.C. and Shumak, K., New Eng. J. Med. 289: 1385, 1973.PubMedCrossRefGoogle Scholar
  10. 10.
    Gelfand, E.W., Biggar, W.D. and Orange, R.P. Ped. Clin. N. Amer. 21: 745, 1974.Google Scholar
  11. 11.
    Abramson, N., Gelfand, E.W., Jandl, J.H. and Posen, F.S., J. Exp. Med. 132: 1207, 1970.PubMedCrossRefGoogle Scholar
  12. 12.
    Perlmann, P. and Maennan, I.C.M., Progress in Immunology II, 3: 347, 1947Google Scholar

Copyright information

© Plenum Press, New York 1976

Authors and Affiliations

  • Erwin W. Gelfand
    • 1
  1. 1.Department of ImmunologyThe Hospital For Sick ChildrenTorontoCanada

Personalised recommendations